Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Raw Materials (2022 - 2025)

BioXcel Therapeutics has reported Raw Materials over the past 4 years, most recently at $317000.0 for Q4 2025.

  • Quarterly results put Raw Materials at $317000.0 for Q4 2025, down 37.35% from a year ago — trailing twelve months through Dec 2025 was $317000.0 (down 37.35% YoY), and the annual figure for FY2025 was $317000.0, down 37.35%.
  • Raw Materials for Q4 2025 was $317000.0 at BioXcel Therapeutics, down from $394000.0 in the prior quarter.
  • Over the last five years, Raw Materials for BTAI hit a ceiling of $935000.0 in Q4 2023 and a floor of $317000.0 in Q4 2025.
  • Median Raw Materials over the past 4 years was $682000.0 (2022), compared with a mean of $650800.0.
  • Biggest five-year swings in Raw Materials: surged 37.1% in 2023 and later crashed 52.7% in 2025.
  • BioXcel Therapeutics' Raw Materials stood at $682000.0 in 2022, then surged by 37.1% to $935000.0 in 2023, then tumbled by 45.88% to $506000.0 in 2024, then plummeted by 37.35% to $317000.0 in 2025.
  • The last three reported values for Raw Materials were $317000.0 (Q4 2025), $394000.0 (Q3 2025), and $433000.0 (Q2 2025) per Business Quant data.